News | Vena Cava Filters | January 02, 2018

Florida Law Firm Sues Cordis, Blames Death on IVC Filter

Suit attributes patient death to alleged defective design and manufacture, deceptive marketing and failure to warn of product’s risks

Florida Law Firm Sues Cordis, Blames Death on IVC Filter

January 2, 2018 — Osborne & Associates Law Firm, P.A., of Boca Raton, Fla., has filed suit in Palm Beach Circuit Court, alleging a New Jersey man died from complications related to an inferior vena cava (IVC) filter manufactured by Cordis Corp. of Miami Lakes.

The products liability suit attributes Martino Convertino’s death to the manufacturer’s alleged defective design and manufacture, deceptive marketing and failure to warn of the product’s risks.

“This is among the first death lawsuits in South Florida against Cordis for this product, and this is a big step in a growing body of litigation around the country against manufacturers of IVC filters that not only fail to protect people, but place them at greater risk of injury and even death,” said Joseph A. Osborne, who is representing the family in the case.

The IVC filter is designed to protect the heart and lungs from fatal blood clots. It is a nickel titanium alloy device with a double basket to filter or “catch” clots that travel to the heart and lungs through the IVC. The U.S. Food and Drug Administration (FDA) has approved these filters to prevent death from pulmonary embolism and thrombosis. Osborne’s suit says that manufacturing defects make the TrapEase prone to fracture, disintegration and migration through the blood system, thereby endangering patients.

 

On March 23, 2016, Martino Convertino checked into the emergency room of St. Joseph’s Regional Medical Center in Paterson, N.J., with lightheadedness and severe pain in his back and legs. He went into shock and died from thrombosis the next day. The 37-page, five-count suit blames Convertino’s death on the Cordis TrapEase IVC filter, which had been implanted in October 2012, when Convertino was 68. The suit, which also cites Cordis’s earlier OptEase IVC filter, was filed by his widow, Carmine Convertino.

According to the suit, Convertino’s autopsy cited rupture of his inferior vena cava. A nurse forwarded a copy of the autopsy to Cordis in May 2016.

While IVC filters have been on the market since the 1960s, from 2000 to 2003 manufacturers brought the first IVC filters to market with the option to remove them. The first three cleared were the OptEase, made by Cordis and Johnson & Johnson, the Recovery Filter (C.R. Bard Inc.) and the Gunther Tulip Filter (Cook Medical).

“This market expansion and off-label use was driven by baseless marketing campaigns made by Defendants targeting bariatric, trauma, orthopedic and cancer patient populations,” the suit says.

“The medical community has just recently begun to awaken to the fact that despite marketing claims by Defendants, there is no reliable evidence that any IVC filter offers a benefit and that these products expose patients to substantial safety hazards,” the suit says.

“Not only do TrapEase and OptEase filters fail at alarming rates, but they also fail at rates substantially higher than other available IVC Filters,” the suit says, citing one study showing a fracture rate of 23 percent for TrapEase filters after 46 months, and another reporting a 64 percent fracture rate after four years.

The suit cites “alarming results” reported in an October 2015 article in the Annals of Surgery, concluding that IVC filters are not only ineffective in preventing thrombosis, but actually cause it to occur.

The Annals reported that twice the percentage of IVC filter patients died or developed pulmonary thrombosis — the very condition the device was supposed to prevent — as those who did not receive the device.

IVC filter use overall peaked in the United States in 2010 and has since declined. A recent article posted by JAMA cited a U.S. Food and Drug Administration (FDA) device safety advisory as contributing to that dropoff. A growing body of medical literature and news reports have thrown light on the dangers of these devices, according to Osborn & Associates.

Litigation against manufacturers is moving through courts nationally, with multidistrict federal litigation against Cook Medical in Indiana, where the first case went to trial in October, and against Bard, where the first case goes to trial in Phoenix in March 2018. Osborne is on the national plaintiff’s steering committee in the Bard IVC litigation.

Growing clusters of state cases are developing against Cordis in California, and, now, in Florida. Osborne represents patients in IVC cases around the country, including the Palm Beach County case Heather Lilla v. Cordis Corp. et al., Case No 50-2016-CA-006931, Fifteenth Judicial Circuit, Palm Beach County, Fl. That pending case alleges Raymond Lilla died at St. Mary’s Hospital in West Palm Beach in March 2016 of complications resulting from the defective IVC filter.

For more information: www.oa-lawfirm.com, www.cordis.com

Related Content

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019 | Dave Fornell, Editor
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Overlay Init